Also known as: 1,3-Benzenediol, 2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-, 1,3-Benzenediol, 2-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-, (1R-trans)-, 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3- benzenediol, (-)-Cannabidiol, Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, trans-(-)- (+7 more)
INCI: CANNABIDIOL (WITH COSING QUALIFIER: "DERIVED FROM EXTRACT OR TINCTURE OR RESIN OF CANNABIS")
Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis (CAS 13956-29-1) is a cosmetic cosmetic ingredient functioning as Skin conditioning; antioxidant; anti-inflammatory (skin protectant). Reported NOAEL =80 mg/kg bw/day in rabbit (New Zealand White; male/female) (FDA); EU Regulation 1223/2009 status: prohibited. Industrial safety data is also available in the chemical safety database. Same-CAS public records also appear in pharmaceutical data.
View industrial chemical safety profile for CAS 13956-29-1 →
For full compliance data across multiple jurisdictions, use the Substance Compliance tool.
Margin of Safety, dermal absorption, and sensitization profile summaries for Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis.
Calculate MoS for your specific formulation with the MoS Calculator.
10 study endpoints found for Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis. NOAEL (No Observed Adverse Effect Level) values are used to calculate the Margin of Safety per SCCS methodology.
| Endpoint | Value | Route | Species | Study Type | Source |
|---|---|---|---|---|---|
| NOAEL | =80 mg/kg bw/day | oral: gavage | rabbit (New Zealand White; male/female) | developmental toxicity teratogenicity | FDA |
| NOAEL | =80 mg/kg bw/day | oral: gavage | rabbit (New Zealand White; male/female) | developmental toxicity teratogenicity | FDA |
| NOAEL | =80 mg/kg bw/day | oral: gavage | rabbit (New Zealand White; male/female) | developmental toxicity teratogenicity | FDA |
| NOAEL | =80 mg/kg bw/day | oral: gavage | rabbit (New Zealand White; male/female) | developmental toxicity teratogenicity | FDA |
| NOAEL | =400 mg/kg bw/day | oral: gavage | mouse (CD-1; male) | repeated dose toxicity oral | FDA |
| NOAEL | =400 mg/kg bw/day | oral: gavage | mouse (CD-1; male) | repeated dose toxicity oral | FDA |
| NOAEL | =400 mg/kg bw/day | oral: gavage | mouse (CD-1; male) | repeated dose toxicity oral | FDA |
| NOAEL | =400 mg/kg bw/day | oral: gavage | mouse (CD-1; male) | repeated dose toxicity oral | FDA |
| NOAEL | =550 mg/kg bw/day | oral: gavage | mouse (CD-1; female) | repeated dose toxicity oral | FDA |
| NOAEL | =550 mg/kg bw/day | oral: gavage | mouse (CD-1; female) | repeated dose toxicity oral | FDA |
Additional regulatory detail beyond the 7-jurisdiction summary: Saudi SFDA, Korea MFDS, ASEAN ACD, Japan/Korea, Brazil/India, and cross-jurisdictional restriction entries.
| Jurisdiction | Status | Max % | Product Type |
|---|---|---|---|
| CN | banned | - | - |
Preliminary editorial summary for Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis — not a computed safety verdict. See the sourced toxicological data above.
Public NOAEL study rows linked to Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis by CAS number or substance name.
Units vary across source rows: mg/kg bw/day, mg/kg/day, mg/kg
Same-CAS public records found in pharmaceutical data.
Same-CAS rows from the pharmaceutical spoke database.
Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis has a safety rating of "MODERATE" in our database. EU status: prohibited. US status: restricted. 10 toxicological study endpoint(s) are available in our database.
Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis EU regulatory status: prohibited. This is based on EU Regulation 1223/2009 and its amendments.
Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis functions as: Skin conditioning; antioxidant; anti-inflammatory (skin protectant). It is classified as a cosmetic ingredient in our database. CAS number: 13956-29-1.
The NOAEL (No Observed Adverse Effect Level) for Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis is =80 mg/kg bw/day based on a developmental toxicity teratogenicity study via oral: gavage route in rabbit (New Zealand White; male/female). A total of 10 study endpoints are available. Source: FDA.
Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis also appears in pharmaceutical data. The cross-vertical cards on this page render same-CAS public rows from the matched databases.
Check Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis compliance across multiple jurisdictions:
Scan any product label with Piro — our free ingredient scanner. Point your camera at the ingredients list and get instant safety scores for every ingredient.
Try Piro Free →Paste any INCI list into the Decoder for instant safety analysis, or calculate the Margin of Safety for Cannabidiol – Derived from Extract or Tincture or Resin of Cannabis in your formulation.